Artisan Partners
VRTX icon

Artisan Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Artisan Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-650,259
Closed -$289M – 376
2025
Q2 		$289M Sell
650,259
-68,872
-10% -$31.7M 0.42% 65
2025
Q1 		$349M Buy
719,131
+54,608
+8% +$25.4M 0.56% 51
2024
Q4 		$268M Buy
664,523
+114,250
+21% +$53M 0.4% 63
2024
Q3 		$256M Buy
550,273
+34,887
+7% +$16.8M 0.38% 68
2024
Q2 		$242M Sell
515,386
-37,496
-7% -$16.3M 0.36% 71
2024
Q1 		$231M Sell
552,882
-23,625
-4% -$9.99M 0.33% 76
2023
Q4 		$235M Sell
576,507
-9,334
-2% -$3.45M 0.36% 78
2023
Q3 		$204M Sell
585,841
-53,955
-8% -$18.9M 0.35% 78
2023
Q2 		$225M Sell
639,796
-1,759
-0.3% -$593K 0.36% 75
2023
Q1 		$202M Buy
641,555
+453,085
+240% +$136M 0.33% 78
2022
Q4 		$54.4M Sell
188,470
-39,234
-17% -$12M 0.1% 200
2022
Q3 		$65.9M Sell
227,704
-150,876
-40% -$43.4M 0.12% 168
2022
Q2 		$107M Sell
378,580
-95,813
-20% -$25.6M 0.18% 131
2022
Q1 		$124M Buy
474,393
+12,079
+3% +$2.87M 0.16% 149
2021
Q4 		$102M Sell
462,314
-2,717
-0.6% -$528K 0.12% 172
2021
Q3 		$84.4M Sell
465,031
-1,078
-0.2% -$210K 0.1% 196
2021
Q2 		$94M Buy
+466,109
New +$97.5M 0.11% 186
2020
Q4 		– Sell
-45,582
Closed -$12.4M – 368
2020
Q3 		$12.4M Buy
+45,582
New +$12.6M 0.02% 298
2015
Q4 		– Sell
-60,637
Closed -$6.32M – 396
2015
Q3 		$6.32M Buy
60,637
+1,889
+3% +$243K 0.01% 324
2015
Q2 		$7.25M Sell
58,748
-304
-0.5% -$38.3K 0.01% 324
2015
Q1 		$6.97M Buy
+59,052
New +$7.08M 0.01% 332
2013
Q4 		– Sell
-830,268
Closed -$63M – 369
2013
Q3 		$63M Buy
830,268
+70,868
+9% +$5.64M 0.12% 179
2013
Q2 		$60.7M Buy
+759,400
New +$55.9M 0.13% 175

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Artisan Partners's VRTX Position: Q3 2025 in Review

Artisan Partners sold out of Vertex Pharmaceuticals (VRTX) in Q3 2025, closing a stake of 650,259 shares — an estimated $289M sold.

Artisan Partners first reported a position in VRTX in Q2 2013 and held it in 23 quarters. The position peaked at $349M in Q1 2025. 1,519 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

  • Artisan Partners reported no remaining Vertex Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Artisan Partners sold 650,259 Vertex Pharmaceuticals shares in Q3 2025, an estimated $289M.
  • Artisan Partners first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 23 quarters.
  • Artisan Partners's Vertex Pharmaceuticals position peaked at $349M in Q1 2025.
  • 1,519 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on Artisan Partners's 13F filing for Q3 2025, filed 12 Nov 2025.